Evidence map›Paper›PMID 34926792›Full record

ArticleAdvanced therapeutics2021

Self-Assembled Peptide Amphiphile Nanofibers for Controlled Therapeutic Delivery to the Atherosclerotic Niche.

Erica B Peters, Mark R Karver, Kui Sun, David C Gillis, Suvendu Biswas, Tristan D Clemons, Wenhan He, Nick D Tsihlis, Samuel I Stupp, Melina R Kibbe

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Cell-Laden Supramolecular and Covalent Polymer Hydrogels for High-Shear Delivery: A Design of Experiments Approach.Chemistry of materials : a publication of the American Chemical Society · 2026
    Article
  2. Toward development of a dynamic supramolecular peptide therapy for acute ischemic stroke.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Erica B PetersDepartment of Surgery, Division of Vascular Surgery and Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Mark R KarverSimpson Querrey Institute, Northwestern University, Chicago, IL 60611, USA.
Kui SunDepartment of Surgery, Division of Vascular Surgery and Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
David C GillisDepartment of Surgery, Division of Vascular Surgery and Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Suvendu BiswasSimpson Querrey Institute, Northwestern University, Chicago, IL 60611, USA.
Tristan D ClemonsSimpson Querrey Institute, Northwestern University, Chicago, IL 60611, USA.
Wenhan HeDepartment of Surgery, Division of Vascular Surgery and Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Nick D TsihlisDepartment of Surgery, Division of Vascular Surgery and Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Samuel I StuppSimpson Querrey Institute, Northwestern University, Chicago, IL 60611, USA.
Melina R KibbeDepartment of Surgery, Division of Vascular Surgery and Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
University of North Carolina at Chapel Hill · USNorthwestern University · US

Funding

Novel Vehicles for Targeted Cardiovascular RepairR01HL116577 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KIBBE, MELINA RAE, STUPP, SAMUEL I · 2013 to 2016
$4.3M
NHLBI NIH HHS R01 HL116577
6 · The paper itself

Abstract

Atherosclerotic plaque remains the leading contributor to cardiovascular disease and requires invasive surgical procedures for its removal. Nanomedicine offers a minimally invasive approach to alleviate plaque burden by targeted therapeutic delivery. However, nanocarriers are limited without the ability to sense and respond to the diseased microenvironment. In this study, targeted self-assembled peptide amphiphile (PA) nanofibers were developed that cleave in response to biochemical cues expressed in atherosclerotic lesions-reactive oxygen species (ROS) and intracellular glutathione-to deliver a liver X receptor agonist (LXR) to enhance macrophage cholesterol efflux. The PAs released LXR in response to physiological levels of ROS and reducing agents and could be co-assembled with plaque-targeting PAs to form nanofibers. The resulting LXR PA nanofibers promoted cholesterol efflux from macrophages

Indexed as

cardiovascular diseasedrug deliverynanomedicineNanotechnologypeptide amphiphiles

Identifiers

PMID34926792
PMCPMC8680456
OpenAlexW3185888037

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.